<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982409</url>
  </required_header>
  <id_info>
    <org_study_id>NCT02038508</org_study_id>
    <nct_id>NCT01982409</nct_id>
  </id_info>
  <brief_title>Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children</brief_title>
  <official_title>A Study of Immune Persistence After Inoculated With One-dose Freeze-dried Live Attenuated Varicella Vaccine in Children Aged 1-6 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changchun Changsheng Life Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial Institute of Biological Products And Materia Medica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changchun Changsheng Life Science and Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the persistence of protection, duration of&#xD;
      protection, safety and breakthrough infection rates afforded by live attenuated varicella&#xD;
      vaccine in children over a 5-year period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune protective effect and persistence after inoculated with live attenuated varicella vaccine</measure>
    <time_frame>Before vaccination, six weeks and every year in 5 years study period after inoculation of the live varicella vaccine</time_frame>
    <description>Clinical subjects are drawn 3ml's vein blood，respectively before vaccination, six weeks and every year in 5 years study period after inoculation of the live varicella vaccine. FAMA methods are used to test antibody rate of pox virus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breakthrough rate, duration and severity of varicella in vaccinated children</measure>
    <time_frame>5 years period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Up to 4 weeks after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Chickenpox</condition>
  <arm_group>
    <arm_group_label>Live Attenuated Varicella Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Varicella Vaccine</intervention_name>
    <arm_group_label>Live Attenuated Varicella Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant are healthy children aged 1-6 years, who has inquired for medical history&#xD;
             and physical examination, and met the requirement of the vaccine trial&#xD;
&#xD;
          -  Parent/legal acceptable representative is willing and able to understand the protocol&#xD;
             requirements and provide informed consent&#xD;
&#xD;
          -  Subject and parent/guardian able to attend all scheduled visits and comply with all&#xD;
             trial procedures&#xD;
&#xD;
          -  Body temperature ≤37℃&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant with previous history of chickenpox or zoster&#xD;
&#xD;
          -  Receipt of varicella vaccine&#xD;
&#xD;
          -  Reported the family history of allergies, convulsions, epilepsy and mental illness&#xD;
&#xD;
          -  Known allergy to any constituent of the vaccine&#xD;
&#xD;
          -  Known serve illness, in a fever, acute infection and chronic disease activity&#xD;
&#xD;
          -  Receipt of steroid&#xD;
&#xD;
          -  Reported the history of thrombocytopenia or other coagulation disorders, which may&#xD;
             cause&#xD;
&#xD;
          -  Known or suspected impairment of immunologic function, or receipt of immunosuppressive&#xD;
             therapy or immunoglobulin since birth&#xD;
&#xD;
          -  Known congenital malformation, developmental disorders and severe chronic disease&#xD;
             (e.g. Down's syndrome, diabetes, sickle cell anemia and neurologic disorders)&#xD;
&#xD;
          -  Known dermatopathy with allergy, herpes, fester, and fungal infection&#xD;
&#xD;
          -  Receipt of whole blood, blood plasma or immunoglobulin in the 3 months preceding the&#xD;
             trial vaccination&#xD;
&#xD;
          -  Reported the history of acute illness had need systemic antibiotics or anti-viral&#xD;
             treatment of infections in the 7 days preceding the trial vaccination&#xD;
&#xD;
          -  Participant with fever(temperature≥ 38℃) in the days&#xD;
&#xD;
          -  Any condition, which, in the opinion of the investigator, would pose a health risk to&#xD;
             the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maoming Center for Disease Control and Prevention</name>
      <address>
        <city>Maoming</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>November 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

